Hidden in Plain Sight

Recently, I shared with a friend poised to begin treatment with Evenity the observation that all but one of the drugs used to treat osteoporosis have been available for over 15 years. Rheumatologists sometimes marvel at that. Evenity is the youngster of the armamentarium, launched in 2015, and insurance companies make it difficult to get it, even though a commonly used anabolic alternative like Prolia (and its biosimilars) isn’t easily stopped once started due to rebound effects not reversed by Evenity. In fact, my friend’s mighty struggle to get approval for Evenity as first-line therapy is what brought the topic up in the first place.